WallStSmart

McCormick & Company Incorporated (MKC-V)vsNiagen Bioscience, Inc. (NAGE)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

McCormick & Company Incorporated generates 5854% more annual revenue ($7.69B vs $129.08M). MKC-V leads profitability with a 19.4% profit margin vs 12.4%. MKC-V trades at a lower P/E of 8.4x. MKC-V earns a higher WallStSmart Score of 59/100 (C).

MKC-V

Buy

59

out of 100

Grade: C

Growth: 4.7Profit: 7.5Value: 8.0Quality: 5.0
Piotroski: 4/9Altman Z: 1.58

NAGE

Hold

40

out of 100

Grade: D

Growth: 4.7Profit: 6.0Value: 6.0Quality: 8.5
Piotroski: 4/9Altman Z: 2.02
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MKC-VUndervalued (+77.9%)

Margin of Safety

+77.9%

Fair Value

$325.30

Current Price

$46.05

$279.25 discount

UndervaluedFair: $325.30Overvalued

Intrinsic value data unavailable for NAGE.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MKC-V4 strengths · Avg: 8.8/10
P/E RatioValuation
8.4x10/10

Attractively priced relative to earnings

Return on EquityProfitability
21.4%9/10

Every $100 of equity generates 21 in profit

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

Revenue GrowthGrowth
17.4%8/10

17.4% revenue growth

NAGE4 strengths · Avg: 8.8/10
Debt/EquityHealth
0.0310/10

Conservative balance sheet, low leverage

Return on EquityProfitability
22.6%9/10

Every $100 of equity generates 23 in profit

P/E RatioValuation
13.1x8/10

Attractively priced relative to earnings

Price/BookValuation
2.4x8/10

Reasonable price relative to book value

Areas to Watch

MKC-V3 concerns · Avg: 3.3/10
PEG RatioValuation
2.044/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.584/10

Distress zone — elevated risk

EPS GrowthGrowth
-57.1%2/10

Earnings declined 57.1%

NAGE4 concerns · Avg: 2.5/10
Market CapQuality
$197.02M3/10

Smaller company, higher risk/reward

Operating MarginProfitability
2.4%3/10

Operating margin of 2.4%

Revenue GrowthGrowth
-4.3%2/10

Revenue declined 4.3%

EPS GrowthGrowth
-75.0%2/10

Earnings declined 75.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : MKC-V

The strongest argument for MKC-V centers on P/E Ratio, Return on Equity, Price/Book. Profitability is solid with margins at 19.4% and operating margin at 17.8%. Revenue growth of 17.4% demonstrates continued momentum.

Bull Case : NAGE

The strongest argument for NAGE centers on Debt/Equity, Return on Equity, P/E Ratio.

Bear Case : MKC-V

The primary concerns for MKC-V are PEG Ratio, Altman Z-Score, EPS Growth.

Bear Case : NAGE

The primary concerns for NAGE are Market Cap, Operating Margin, Revenue Growth.

Key Dynamics to Monitor

MKC-V profiles as a growth stock while NAGE is a declining play — different risk/reward profiles.

NAGE carries more volatility with a beta of 2.02 — expect wider price swings.

MKC-V is growing revenue faster at 17.4% — sustainability is the question.

MKC-V generates stronger free cash flow (112M), providing more financial flexibility.

Bottom Line

MKC-V scores higher overall (59/100 vs 40/100), backed by strong 19.4% margins and 17.4% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

McCormick & Company Incorporated

CONSUMER DEFENSIVE · PACKAGED FOODS · USA

McCormick & Company is an American multinational food company that manufactures, markets, and distributes spices, seasoning mixes, condiments, and other flavoring products to retail outlets, food manufacturers, and foodservice businesses.

Niagen Bioscience, Inc.

CONSUMER DEFENSIVE · PACKAGED FOODS · USA

Niagen Bioscience, Inc. is a bioscience company engages in developing healthy aging products. The company is headquartered in Los Angeles, California.

Want to dig deeper into these stocks?